CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Consensus Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 02/12/2024 GMT			5-day change	1st Jan Change
201.25 ^USD	+1.10%		-0.02%	-14.87%

11-26	Goldman Sachs Adjusts Price Target on Charles River Laboratories International to $220 From $240, Maintains Buy Rating	MT
11-25	Redburn Atlantic Adjusts PT on Charles River Laboratories International to $171 From $151, Maintains Sell Rating	MT

Evolution of the Average Target: Charles River Laboratories International, Inc.

average-target-price-chart CHARLES-RIVER-LABORATORIE

Evolution of the Target Price: Charles River Laboratories International, Inc.

target-price-consensus-chart CHARLES-RIVER-LABORATORIE

Changes in Analyst Recommendations: Charles River Laboratories International, Inc.

5fbadf38e40f10c0b474d2f.1powdrbtrJf-n3kApdJjpdLG01k2OCbJVwflTFKqxGI.jN8dOOmIn9zT_lRTy6Uu7rCCiQ1sYWujOlDSPBDt8VOBq2Q0xrjK-prtMA~85cab5d39f91bd9615076d9a8e508fb3

Analysts' recommendations: Charles River Laboratories International, Inc.

Goldman Sachs Adjusts Price Target on Charles River Laboratories International to $220 From $240, Maintains Buy Rating	11-26	MT
Redburn Atlantic Adjusts PT on Charles River Laboratories International to $171 From $151, Maintains Sell Rating	11-25	MT
Baird Adjusts Price Target on Charles River Laboratories International to $197 From $211, Maintains Neutral Rating	11-25	MT
Analyst recommendations: Biogen, HP, Moderna, Shell...	11-18
TD Cowen Adjusts Price Target on Charles River Laboratories International to $227 From $203, Maintains Hold Rating	11-11	MT
Barrington Adjusts Price Target on Charles River Laboratories International to $212 From $194, Maintains Outperform Rating	11-08	MT
Morgan Stanley Raises Charles River Laboratories International's Price Target to $225 From $215	11-07	MT
UBS Adjusts Price Target on Charles River Laboratories International to $250 From $240, Maintains Buy Rating	11-07	MT
Baird Adjusts Charles River Laboratories International Price Target to $211 From $190, Maintains Neutral Rating	11-07	MT
JPMorgan Adjusts Charles River Laboratories International Price Target to $215 From $195, Maintains Neutral Rating	11-07	MT
Evercore ISI Adjusts Charles River Laboratories International Price Target to $225 From $190, Maintains In Line Rating	11-07	MT
Analyst recommendations: Corteva, Dollar Tree, JPMorgan, Microsoft, Palantir...	11-07
Deutsche Bank Raises Charles River Laboratories International Price Target to $250 From $235	11-06	MT
Deutsche Bank Adjusts Charles River Laboratories International Price Target to $235 From $240, Maintains Buy Rating	10-16	MT
Barclays Adjusts Price Target on Charles River Laboratories International to $205 From $210	10-15	MT
Redburn Atlantic Initiates Charles River Laboratories International at Sell With $151 Price Target	10-14	MT
JPMorgan Adjusts Charles River Laboratories International Price Target to $195 From $205, Maintains Neutral Rating	10-14	MT
Redburn Atlantic Initiates Charles River Laboratories International at Sell With $151 Price Target	10-14	MT
Goldman Sachs Adjusts Price Target on Charles River Laboratories International to $240 From $250, Maintains Buy Rating	10-08	MT
Evercore ISI Downgrades Charles River Laboratories International to In Line From Outperform, Adjusts PT to $190 From $225	10-07	MT
BofA Securities Downgrades Charles River Laboratories International to Neutral From Buy on Biopharma Concerns, Price Target is $215	10-02	MT
Citigroup Downgrades Charles River Laboratories International to Sell From Neutral, Adjusts PT to $175 From $215	10-01	MT
Baird Adjusts Charles River Laboratories International Price Target to $190 From $191	09-20	MT
Mizuho Adjusts Price Target on Charles River Laboratories International to $210 From $235, Maintains Neutral Rating	08-13	MT
TD Cowen Adjusts Price Target on Charles River Laboratories International to $203 From $228, Maintains Hold	08-12	MT

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					+8.65%
	LONZA GROUP AG					+20.20%
	IQVIA HOLDINGS INC.					+25.56%
	CELLTRION, INC.					+32.06%
	ICON PUBLIC LIMITED COMPANY					+31.30%
	MODERNA, INC.					+77.46%
	UNITED THERAPEUTICS CORPORATION					+3.17%
	BIO-TECHNE CORPORATION					+13.12%
	MEDPACE HOLDINGS, INC.					+2.14%
	TEMPUS AI, INC					-8.70%
	Average					+20.50%
	Weighted average by Cap.					+23.72%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

201.25USD

Average target price

216.27USD

Spread / Average Target

+7.47%

High Price Target

260.00USD

Spread / Highest target

+29.19%

Low Price Target

164.00USD

Spread / Lowest Target

-18.51%

Analyst Consensus Detail

consensus-detail-chart CHARLES-RIVER-LABORATORIE

Consensus revision (last 18 months)

consensus-revision-chart CHARLES-RIVER-LABORATORIE

Analysts covering the company

Goldman Sachs
Redburn Atlantic
Baird
TD Cowen
Barrington Research
Morgan Stanley
UBS
JPMorgan Chase
Evercore ISI
Deutsche Bank Securities
Barclays
BofA Securities
Citigroup
Mizuho Securities
Jefferies & Co.
Zacks Investment Research
Argus
Stephens Inc.
Guggenheim
Wells Fargo Securities
Credit Suisse
KeyBanc Capital Markets
Truist Securities
J.P. Morgan Chase